Bio-Conference Calender

Part of CHI's 19th International Molecular Med TRI-CON 2012

Register for TRI-CON ALL ACCESS & SAVE $1200

Top Five Reasons to Attend:

Network with industry leaders in translational medicine and research.

Learn collaboration strategies from both the academic and industry perspective.

Hear the latest in translational informatics that cross therapeutic areas and improve data management and knowledge sharing within an organization.

Discuss pre-competitive collaborations and biomarker strategies in interactive panel sessions throughout the program.

...

Create collaborative relationships by participating in roundtable discussions on a variety of topics.

Conference Agenda

DAY 1 - TRANSLATIONAL IMAGING

Impact and Translational Opportunities of Pre-Clinical Imaging in Biomarker Discovery and Drug Development - Paul McCracken, Ph.D., Director, Imaging, Eisai Research Institute

Integrating Imaging in Early Drug Development: Lessons Learned from the VEGFR TKI Experience - Glenn Liu, M.D., Associate Professor, Medicine, Carbone Cancer Center, Wisconsin Institute for Medical Research, University of Wisconsin

Translational Imaging for De-risking Pharmaceutical Pipelines - Yanping Luo, Ph.D., Group Leader, Translational Imaging, Global Pharmaceutical R&D, Abbott Laboratories

PET Imaging as a Quantitative Biomarker in CNS Drug Development: Illustration by Examples - Yiyun Henry Huang, Ph.D., Associate Professor, Co-Director, PET Center, Department of Diagnostic Radiology, Yale University

KEYNOTE PRESENTATION: Use of Biomarkers and Translational Science to Improve and Accelerate

Oncology Drug Development - J. Carl Barrett, Ph.D., Vice President, Translational Medicine, AstraZeneca

DAY 2

PANEL DISCUSSION: How Have Biomakers Been Applied in Clinical Development?

Moderator: Prakash Purohit, Ph.D., Associate Director, Scientific Affairs, IPSEN Biomeasure, Inc.

Panelists:

Dominic G. Spinella, Ph.D., Head, Translational and Molecular Medicine, Pfizer

Donald Bergstrom, Head, Translational Medicine, sanofi aventis

Suso Platero, Ph.D., Director, Oncology Biomarkers, Centocor, Ortho Biotech Oncology Research & Development, a unit of J&J PRD, LLC

Panelists from informatics, biology, discovery, regulatory to discuss how to much more efficiently turn biomarker assays into diagnostics. What challenges are there? What strategies are best for future use of biomarkers for clinical development? Case examples will be used.

Translational Research for Targeted Therapies Using an Integrated Proteomic Approach

Corinne Ramos, Ph.D., Executive Director, Clinical Research, Theranostics Health

TRANSLATIONAL BIOMARKERS

Biomarkers: How to Find them and Apply Them in Clinical Trials - Suso Platero, Ph.D., Director, Oncology Biomarkers, Centocor, Ortho Biotech Oncology Research & Development, a unit of J&J PRD, LLC

Back to Biomarker Basics for Drug Development - Terry Walker, Ph.D., Director, Translational Immunology, Immunology & Autoimmunity Research Unit, Pfizer

Molecular Profiling of Breast Cancer Trial Sets to Unravel Driving Oncogenic Hubs and Parallel Pathways - Brian Leyland-Jones, M.D., Ph.D., Director, Winship Cancer Institute,Emory University

Use of Biomarkers for Detecting Target Engagement and Mechanism-Based AEs in Clinical Trials of TRPV1 Antagonists - Samer Eid, Ph.D.,Team Leader, Pain & Migraine Research, Neuroscience Drug

Discovery, Merck Research Laboratories

Biomarker Discovery and Validation: What is Missing - Joerg Heyer, Ph.D., Director, Genetic Models, Translational Research, AVEO Pharmaceuticals

KEYNOTE PRESENTATION: Cancer Pharmacology in Translational Medicine - Z. Alex Cao, Ph.D., Associate Director, Oncology Translational Research, Novartis Oncology Translational Medicine

DAY 3

CENTERS OF EXCELLENCE: ACADEMICS IN TRANSLATIONAL RESEARCH

Translational Research at Scripps Florida - Patrick Griffin, Ph.D., Director, Translational Research, The Scripps Research Institute

Translating Innovation into Personalized Medicine: A Centralized Approach for Fostering Research and Engaging Physicians in a Large National Community Hospital Network Jeffrey M. Otto, Ph.D., M.B.A., National Director, Catholic Health Initiative's Center for Translational Research

Academic Leadership in Translational Science Bruce A. Sullenger, Ph.D., Director of the Duke Center for Translational Research, Joseph and Dorothy Beard Professor, Department of Surgery, Duke

University Medical Center

T-Cell Immunotherapy at UPenn: An Integrated Academic Translational Model for Success - Michael Kalos, Ph.D., Director, Translational and Correlative Studies Laboratory, University of Pennsylvania School of Medicine

Collaboration in Translational Science: Leveraging the Best of Both Worlds Moderator: Patricia McDonald, Ph.D., Associate Scientific Director, Translational Research, The Scripps Research Institute

Open discussion focused on the academic-industry collaboration, identification of niche expertise within an academic organization, cultural differences of pharma and academic and how to work within changing timelines/resources/personnel. Audience participation is encouraged.

INFORMATICS FOR TRANSLATIONAL SCIENCE

Informatics Tools for Translational Science: Bench to Bedside and Back - James Cai, Ph.D., Head, Disease & Translational Informatics, Pharma Research & Early Development (pRED) Informatics, F. Hoffmann-La Roche, Inc.

Building a Translational Informatics Infrastructure Organically - Shoibal Datta, Ph.D., Associate Director, R&D Information Technology, Therapeutic Areas & Translational Medicine, Biogen Idec, Inc.